Vitreomacular Traction
What Is Vitreomacular Traction
The vitreous is a clear, gel-like substance that fills the space between the lens and the retina. It helps maintain the shape of the eye and allows light to pass through to the retina. In youth, the vitreous is firmly attached to the retinal surface, particularly at the optic nerve, the macula, and along the retinal blood vessels.
As part of normal aging, the vitreous gradually shrinks and liquefies, eventually separating from the retina in a process called posterior vitreous detachment (PVD). Posterior vitreous detachment occurs in the majority of people by age 70 and is the most common cause of new floaters (American Academy of Ophthalmology). In most people, this separation is smooth and causes no lasting problems. In VMT, however, the vitreous fails to release cleanly from the macula. The remaining attachment creates traction that pulls on the delicate macular tissue, potentially distorting its structure and impairing central vision.
VMT is classified by the size of the attachment area. Focal VMT involves an adhesion of 1,500 microns or less and tends to be associated with a more concentrated pulling force on the macula. Broad VMT involves a wider area of attachment exceeding 1,500 microns. The type of adhesion can influence symptoms, the likelihood of spontaneous resolution, and treatment decisions.
Symptoms and Diagnosis
Many patients with mild VMT experience no symptoms at all, and the condition may be discovered during a routine dilated eye exam. When symptoms do occur, they often include blurred central vision, visual distortion where straight lines appear wavy or bent (a symptom known as metamorphopsia), difficulty reading fine print, and a noticeable decrease in visual clarity. Symptoms typically affect one eye, though VMT can eventually develop in both eyes.
Optical coherence tomography (OCT) is the primary tool used to diagnose VMT. This noninvasive imaging test produces detailed cross-sectional images of the macula and vitreous interface, revealing the adhesion, any associated macular distortion, and complications such as cyst formation. OCT allows measurement of the extent of traction, monitoring of changes over time, and determination of when intervention may be warranted.
Several other macular conditions share symptoms with VMT, including epiretinal membranes, cystoid macular edema, and central serous retinopathy. A thorough retinal examination with OCT helps distinguish VMT from these conditions and guides the appropriate treatment plan.
Risk Factors and Who Is Affected
VMT is most commonly diagnosed in adults over 60 as part of the natural aging process of the vitreous. The vitreous begins to liquefy and shrink in midlife, and the risk of an abnormal adhesion at the macula increases as this process progresses. Women appear to be affected slightly more often than men.
Patients with a history of certain eye conditions may have a higher risk of developing VMT. These include diabetic eye disease, prior uveitis or other ocular inflammation, high myopia (nearsightedness), and previous intraocular surgery. Any condition that alters the vitreous structure or the vitreomacular interface can predispose a person to abnormal adhesion.
If left unmonitored, VMT can progress to more serious conditions. Persistent traction may lead to the formation of a macular hole, a full-thickness defect in the macular tissue that often requires surgery to repair. VMT can also contribute to the accumulation of subretinal fluid or the development of intraretinal cysts, both of which can worsen visual distortion and central vision loss.
Treatment Options for Vitreomacular Traction
Many cases of VMT resolve on their own when the vitreous eventually completes its separation from the macula. If symptoms are mild and OCT imaging shows minimal macular distortion, a watchful waiting approach with regular follow-up exams may be recommended. During this period, OCT scans are performed at scheduled intervals to track any changes in the adhesion or macular architecture.
Ocriplasmin (marketed as Jetrea) is an injectable enzyme that can dissolve the protein bonds holding the vitreous to the macula. It is administered as a single intravitreal injection in the office and is most effective for focal VMT without a large macular hole. Studies show that ocriplasmin successfully releases the vitreomacular adhesion in approximately 26 percent of treated eyes, making it a reasonable option for select patients who want to avoid surgery.
When VMT causes significant symptoms, progressive macular changes, or a macular hole, surgical intervention with pars plana vitrectomy is typically recommended. During this outpatient procedure, the vitreous gel is carefully removed, releasing the traction on the macula. A gas bubble may be placed inside the eye afterward to support the macula as it heals. Vitrectomy for VMT has a high success rate, with most patients experiencing improvement or stabilization of their central vision.
Recovery from vitrectomy generally takes several weeks. Prescribed eye drops are used to prevent infection and reduce inflammation during the healing period. If a gas bubble is placed in the eye, certain positioning requirements and activity restrictions will apply until the bubble absorbs naturally, including avoiding air travel. Detailed aftercare instructions and scheduled follow-up appointments help monitor progress throughout recovery.
Frequently Asked Questions
Yes, in many cases the vitreous eventually completes its separation from the macula without any intervention. Studies suggest that spontaneous release occurs in roughly one-third of VMT cases over time. The condition is monitored closely with OCT imaging to confirm resolution and ensure no complications develop during the waiting period.
VMT refers to the pulling force exerted on the macula by an incompletely separated vitreous. A macular hole is a full-thickness opening in the macular tissue that can develop as a consequence of prolonged or severe VMT. Not all cases of VMT progress to a macular hole, but early detection through regular imaging helps with timely intervention before a hole forms.
Most patients notice gradual improvement in the weeks following surgery, though complete visual recovery can take two to three months. The timeline depends on factors such as the duration and severity of traction before surgery, whether a gas bubble was placed, and the overall health of the retina. Follow-up visits are scheduled at regular intervals to track progress.
Face-down positioning is more commonly required after macular hole repair than after vitrectomy for VMT alone. However, if a gas bubble is used and the surgeon determines that positioning will support healing, specific instructions will be provided. Most patients who undergo vitrectomy for VMT without a concurrent macular hole have fewer positioning restrictions.
VMT typically develops in one eye at a time, but because the underlying cause is an age-related vitreous change that occurs in both eyes, the fellow eye can be affected as well. If VMT has been diagnosed in one eye, the other eye should also be monitored during appointments to watch for early signs of a similar adhesion.
Untreated VMT may remain stable for months or years, gradually worsen, or spontaneously resolve. In cases where the traction increases, it can lead to a macular hole, progressive intraretinal cyst formation, or worsening visual distortion. Regular monitoring with OCT imaging ensures that treatment can be initiated promptly if the condition begins to progress.
What our Patients say
4.8
Reviews
(3547)